Literature DB >> 3277171

Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases.

M Gonzatti-Haces1, A Seth, M Park, T Copeland, S Oroszlan, G F Vande Woude.   

Abstract

The proteins encoded by the human TPR-MET oncogene (p 65tpr-met) and the human MET protooncogene (p140met) have been identified. The p65tpr-met and p140met, as well as a truncated TPR-MET product expressed in Escherichia coli, p50met, are autophosphorylated in vitro on tyrosine residues. Using the immunocomplex kinase assay, p140met activity was detected in various human tumor epithelial cell lines. In vivo, p65tpr-met is phosphorylated on both serine and tyrosine residues, while p140met is phosphorylated on serine and threonine. p140met is labeled by cell-surface iodination procedures, suggesting that it is a receptor-like transmembrane protein-tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277171      PMCID: PMC279473          DOI: 10.1073/pnas.85.1.21

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Coupling of peptides to albumin with difluorodinitrobenzene.

Authors:  H S Tager
Journal:  Anal Biochem       Date:  1976-04       Impact factor: 3.365

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 3.  Protein-tyrosine kinases.

Authors:  T Hunter; J A Cooper
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

4.  Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3alpha,6alpha-diphenylglycoluril.

Authors:  M A Markwell; C F Fox
Journal:  Biochemistry       Date:  1978-10-31       Impact factor: 3.162

5.  The met oncogene: a new member of the tyrosine kinase family and a marker for cystic fibrosis.

Authors:  M Park; M Gonzatti-Haces; M Dean; D G Blair; J R Testa; D D Bennett; T Copeland; S Oroszlan; G Vande Woude
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1986

6.  Characterization of the rearranged tpr-met oncogene breakpoint.

Authors:  M Dean; M Park; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

7.  Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.

Authors:  M Park; M Dean; K Kaul; M J Braun; M A Gonda; G Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

8.  Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products.

Authors:  J B Konopka; O N Witte
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

9.  Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.

Authors:  H Ushiro; S Cohen
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

10.  Nucleotide sequence and biochemical activities of the Moloney murine sarcoma virus strain HT-1 mos gene.

Authors:  A Seth; G F Vande Woude
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

View more
  43 in total

1.  The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation.

Authors:  L Naldini; E Vigna; R Ferracini; P Longati; L Gandino; M Prat; P M Comoglio
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

2.  Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor).

Authors:  A Mondino; S Giordano; P M Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

3.  C-terminal truncated forms of Met, the hepatocyte growth factor receptor.

Authors:  M Prat; T Crepaldi; L Gandino; S Giordano; P Longati; P Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

4.  Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.

Authors:  J Voortman; T Harada; R P Chang; J K Killian; M Suuriniemi; W I Smith; P S Meltzer; M Lucchi; Y Wang; G Giaccone
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells.

Authors:  S Lin; D Rusciano; P Lorenzoni; G Hartmann; W Birchmeier; S Giordano; P Comoglio; M M Burger
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

Review 6.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 7.  Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease.

Authors:  Stefanie Gerstberger; Markus Hafner; Manuel Ascano; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  High concentrations of HGF inhibit skeletal muscle satellite cell proliferation in vitro by inducing expression of myostatin: a possible mechanism for reestablishing satellite cell quiescence in vivo.

Authors:  Michiko Yamada; Ryuichi Tatsumi; Keitaro Yamanouchi; Tohru Hosoyama; Sei-ichi Shiratsuchi; Akiko Sato; Wataru Mizunoya; Yoshihide Ikeuchi; Mitsuhiro Furuse; Ronald E Allen
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-09       Impact factor: 4.249

9.  Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.

Authors:  S Rong; S Segal; M Anver; J H Resau; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

10.  MET expression in sporadic renal cell carcinomas.

Authors:  Jong Sun Choi; Mi-Kyung Kim; Jin Won Seo; Yoon-La Choi; Dong Hoon Kim; Yi Kyeong Chun; Young Hyeh Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.